sphingosine-1-phosphate recep. mod. prodrug for multiple sclerosis, proj. human t1/2 of 5d from opt. of prior S1P1 modulators ACS Med. Chem. Lett., Aug. 11, 2020 Bristol-Myers Squibb, Princeton, NJ